Name: UMIN ID:
Unique ID issued by UMIN | UMIN000030142 |
---|---|
Receipt number | R000034427 |
Scientific Title | A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01) |
Date of disclosure of the study information | 2017/11/28 |
Last modified on | 2021/08/12 13:48:04 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2017/11/28 05:44:18 | ||
2 | Update | 2017/11/28 05:45:35 | Key inclusion criteria |
|
3 | Update | 2018/08/12 02:22:27 | Last name of contact person Last name of contact person Name of person sending information Name of person sending information |
|
4 | Update | 2019/04/24 13:18:40 | Public title Public title Scientific Title Scientific Title |
|
5 | Update | 2019/04/24 13:20:10 | Public title Scientific Title |
|
6 | Update | 2019/04/24 14:14:38 | Public title Scientific Title |
|
7 | Update | 2019/12/10 22:42:15 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
8 | Update | 2019/12/10 22:51:48 | Recruitment status Date of IRB Last follow-up date |
|
9 | Update | 2019/12/10 22:52:16 | Number of participants that the trial has enrolled |
|
10 | Update | 2021/06/03 09:29:42 | Recruitment status |
|
11 | Update | 2021/08/12 13:48:04 | Recruitment status Date analysis concluded |